Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 16/20 | 0.68 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5685387 | 0.82 | LTA4H (0.69) | LTA4HACHEPTGS1PTGS2 | |
| SCHEMBL3494088 | 0.81 | LTA4H (0.72) | LTA4HACHE | |
| SCHEMBL2107118 | 0.81 | LTA4H (1.00) | LTA4H | |
| SCHEMBL3494091 | 0.76 | LTA4H (1.00) | LTA4H | |
| SCHEMBL8640498 | 0.73 | LTA4H (0.55) | LTA4HPTGS1PTGS2 | |
| SCHEMBL8637368 | 0.73 | LTA4H (0.55) | LTA4HPTGS1PTGS2 | |
| SCHEMBL7552353 | 0.73 | LTA4H (0.64) | LTA4HACHE | |
| SCHEMBL8107430 | 0.71 | LTA4H (0.76) | LTA4HACHE | |
| SCHEMBL8112098 | 0.70 | LTA4H (0.65) | LTA4HACHE | |
| SCHEMBL7141067 | 0.69 | LTA4H (0.67) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0843549-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4 HYDROLASE INHIBITOR | SEARLE & CO (US) | 2006-04-12 | — | — | EP | claimed |
| US-20050043355-A1 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | claimed |
| US-20030004191-A1 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor | PHARMACIA CORPORATION | 2003-01-02 | — | — | US | claimed |
| EP-0880363-B1 | COMBINATIONS, HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4 HYDROLASE INHIBITOR | SEARLE & CO (US) | 2002-09-11 | — | — | EP | claimed |
| US-6407140-B1 | AUTOIMMUNE DISEASES, GRAFT VERSUS HOST DISEASE AND ORGAN TRANSPLANT SURGERY; PYRAZOLE DERIVATIVE MIXTURE | G.D. SEARLE & CO. | 2002-06-18 | — | — | US | claimed |
| EP-0880363-A1 | COMBINATIONS, HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4? HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-12-02 | — | — | EP | claimed |
| EP-0843549-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4? HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-05-27 | — | — | EP | claimed |
| WO-1997029774-A1 | COMBINATIONS, HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A4 HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1997-08-21 | — | — | WO | claimed |
| WO-1996041625-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A4 HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| US-9617597-B2 | Genetic susceptibility variants associated with cardiovascular disease | DECODE GENETICS EHF (IS) | 2017-04-11 | — | — | US | disclosed |
| US-20100120045-A1 | GENETIC VARIANTS USEFUL FOR RISK ASSESSMENTS OF CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION | DECODE GENETICS EHF (IS) | 2010-05-13 | — | — | US | disclosed |
| US-20100068705-A1 | GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE | DECODE GENETICS EHF (IS) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120045-A1 | GENETIC VARIANTS USEFUL FOR RISK ASSESSMENTS OF CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION | TNNI3, TSG101, ALDH1B1 | LTA4H 91/4885ACHE 4204/4885FFAR1 3019/4885 |
| US-20050043355-A1 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor | LTA4H, LTB4R2, LTB4R | LTA4H 1/4885ACHE 1763/4885FFAR1 609/4885 |
| US-20030004191-A1 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor | LTA4H, LTB4R2, LTC4S | LTA4H 1/4885ACHE 1687/4885FFAR1 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.